Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases-Reference-Cited by-同舟云学术

Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases

Published:2015-03-17 Issue:9 Volume:58 Page:3682-3692
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Hecker Scott J.¹,Reddy K. Raja¹,Totrov Maxim²,Hirst Gavin C.¹,Lomovskaya Olga¹,Griffith David C.¹,King Paula¹,Tsivkovski Ruslan¹,Sun Dongxu¹,Sabet Mojgan¹,Tarazi Ziad¹,Clifton Matthew C.³,Atkins Kateri³,Raymond Amy³,Potts Kristy T.³,Abendroth Jan³,Boyer Serge H.¹,Loutit Jeffrey S.¹,Morgan Elizabeth E.¹,Durso Stephanie¹,Dudley Michael N.¹

Affiliation:

1. Rempex Pharmaceuticals, Inc., A Subsidiary of The Medicines Company, 3033 Science Park Rd., Suite 200, San Diego, California 92121, United States

2. Molsoft L.L.C., 11199 Sorrento Valley Road, San Diego, California 92121, United States

3. Beryllium, 3 Preston Court, Bedford, Massachusetts 01730, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.5b00127

Reference41 articles.

1. Evolution of antimicrobial resistance among Enterobacteriaceae (focus on extended spectrum β-lactamases and carbapenemases)